Cost-effectiveness of the Pharmacogenetic Passport as guidance for dual antiplatelet therapy in acute coronary syndrome patients undergoing primary pecutaneous coronary intervention

Additional Metadata
Keywords	pharmacogenetic passport;cost-effectiveness;economic evaluation
Thesis Advisor	Birnie, E.
Persistent URL	hdl.handle.net/2105/62524
Series	Master Health Economics, Policy and Law
Organisation	Erasmus School of Health Policy & Management
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Kempkes, J.J. (2021, August 31). Cost-effectiveness of the Pharmacogenetic Passport as guidance for dual antiplatelet therapy in acute coronary syndrome patients undergoing primary pecutaneous coronary intervention. Master Health Economics, Policy and Law. Retrieved from http://hdl.handle.net/2105/62524

Publication